PARP Inhibitors in Ovarian Cancer
Open accessAbstract
BACKGROUND: Treatment of Epithelial Ovarian Cancer (EOC), historically based on surgery and platinum doublet chemotherapy, is associated with high risk of relapse and poor prognosis for recurrent disease. In this landscape, the innovative treatment with PARP inhibitors (PARPis) demonstrated an outstanding activity in EOC, and is currently changing clinical practice in BRCA mutant patients. OBJECTIVES: The study aimed to highlight the mechanism of action, pharmacokinetics, clinical activity, indications and current strategies of development of Olaparib, Niraparib, Rucaparib, Talazoparib and Veliparib, the 5 most relevant PARPis. METHODS: We performed a review on Pubmed using 'ovarian cancer' and the name of each PARPi (PARP inhibitor) discussed in the review as Medical Subject Headings (MeSH) keywords. The same search was performed on "clinicaltrial.gov" to identify ongoing clinical trials and on "google. com/patents" and "uspto.gov" for recent patents exploring PARPIs in ovarian cancer. RESULTS: Olaparib, Niraparib and Rucaparib are already approved for the treatment of recurrent EOC and their indications are partially overlapping. Talazoparib and Veliparib are promising PARPis, but currently under investigation in early phase trials. Several studies are evaluating PARPis in monotherapy or in associations, in a wide range of settings (i.e. first line, neoadjuvant, platinum-sensitive and resistant disease). CONCLUSION: PARPis are valuable options in patients with recurrent ovarian cancer with promising activity in different stages of this disease. Further studies are required to better define optimal clinical settings, predictors of response beyond BRCA mutations and strategies to overcome secondary resistance of PARPis therapy in EOC.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Resistance to platinum-based chemotherapy may explain the dark outcomes in malignant AWE.
“Resistance to platinum-based chemotherapy may explain the dark outcomes in malignant AWE, but it remains to be determined whether PARPis have a therapeutic place in recurrent malignant AWE [60].”
From Malignancy in Abdominal Wall Endometriosis: Is There a Way to Avoid It? A Systematic Review (2024) · cites this paper as [60]
PARPis emerged as a therapeutic option in epithelial ovarian cancer with poor prognosis and recurrence.
“PARPis (poly-ADP-ribose polymerase inhibitors) emerged as a therapeutic option in epithelial ovarian cancer with poor prognosis and recurrence.”
From Malignancy in Abdominal Wall Endometriosis: Is There a Way to Avoid It? A Systematic Review (2024) · cites this paper as [60]
Cites
Signatures of mutational processes in human cancer
Initiative, A. P. C. G., Alexandrov, L. B., ICGC Breast Cancer Consortium, ICGC MMML-Seq Consortium, PedBrain, I., Nik-Zainal, S., Wedge, D. C., Aparicio, S. A. J. R., Behjati, S., Biankin, A. V., et al. (2013) · Nature · doi:10.1038/nature12477 · Cited by 9,660 · see citing works
Integrated genomic analyses of ovarian carcinoma
Perou, C. M. (2019) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/hvp3-wg08 · Cited by 7,927 · see citing works
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
Farmer, H., McCabe, N., Lord, C. J., Tutt, A. N. J., Johnson, D. A., Richardson, T. B., Santarosa, M., Dillon, K. J., Hickson, I., Knights, C., et al. (2005) · Nature · doi:10.1038/nature03445 · Cited by 6,683 · see citing works
Instability and decay of the primary structure of DNA
Lindahl, T. (1993) · Nature · doi:10.1038/362709a0 · Cited by 5,679 · see citing works
Genome maintenance mechanisms for preventing cancer
Hoeijmakers, J. H. J. (2001) · Nature · doi:10.1038/35077232 · Cited by 3,939 · see citing works
Antoniou, A., Pharoah, P. D. P., Narod, S., Risch, H. A., Eyfjord, J. E., Hopper, J. L., Loman, N., Olsson, H., Johannsson, O., Borg, Å., et al. (2003) · The American Journal of Human Genetics · doi:10.1086/375033 · Cited by 3,680 · see citing works
Identification of the breast cancer susceptibility gene BRCA2
Wooster, R., Bignell, G. R., Lancaster, J., Swift, S., Seal, S., Mangion, J., Collins, N., Gregory, S. G., Gumbs, C. E., Micklem, G., et al. (1995) · Nature · doi:10.1038/378789a0 · Cited by 3,645 · see citing works
The mechanism of double-strand DNA break repair by the nonhomologous DNA end-joining pathway
Lieber, M. R. (2010) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.052308.093131 · Cited by 2,882 · see citing works
Audeh, M. W., Carmichael, J., Penson, R. T., Friedlander, M., Powell, B., Bell-McGuinn, K. M., Scott, C., Weitzel, J. N., Oaknin, A., Loman, N., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60893-8 · Cited by 2,279 · see citing works
Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors
Murai, J., Huang, S.-Y. N., Das, B. B., Renaud, A., Zhang, Y., Doroshow, J. H., Ji, J. J., Takeda, S., & Pommier, Y. G. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-2753 · Cited by 2,217 · see citing works
Olaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer
Ledermann, J. A., Harter, P., Gourley, C., Friedlander, M. L., Vergote, I. B., Rustin, G. J. S., Scott, C. L., Meier, W., Shapira‐Frommer, R., Safra, T., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1105535 · Cited by 1,891 · see citing works
Pujade-Lauraine, É., Ledermann, J. A., Selle, F., Gebski, V., Penson, R. T., Oza, A. M., Korach, J., Huzarski, T., Poveda, A. M., Pignata, S., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30469-2 · Cited by 1,856 · see citing works
Coleman, R. L., Oza, A. M., Lorusso, D., Aghajanian, C. A., Oaknin, A., Dean, A. P., Colombo, N., Weberpals, J. I., Clamp, A. R., Scambia, G., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)32440-6 · Cited by 1,699 · see citing works
Hallmarks of 'BRCAness' in sporadic cancers
Turner, N. C., Tutt, A. N. J., & Ashworth, A. (2004) · Nature reviews. Cancer · doi:10.1038/nrc1457 · Cited by 1,651 · see citing works
Whole–genome characterization of chemoresistant ovarian cancer
Patch, A., Christie, E. L., Etemadmoghadam, D., Garsed, D. W., George, J., Fereday, S., Nones, K., Cowin, P. A., Alsop, K., Bailey, P. J., et al. (2015) · Nature · doi:10.1038/nature14410 · Cited by 1,551 · see citing works
Ledermann, J. A., Harter, P., Gourley, C., Friedlander, M. L., Vergote, I. B., Rustin, G. J. S., Scott, C. L., Meier, W., Shapira‐Frommer, R., Safra, T., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70228-1 · Cited by 1,437 · see citing works
McCabe, N., Turner, N. C., Lord, C. J., Kluzek, K., Białkowska, A., Swift, S., Giavara, S., O’Connor, M. J., Tutt, A. N. J., Zdzienicka, M. Z., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-0140 · Cited by 1,311 · see citing works
New insights into the molecular and cellular functions of poly(ADP-ribose) and PARPs
Gibson, B. A., & Kraus, W. L. (2012) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3376 · Cited by 1,226 · see citing works
Swisher, E. M., Lin, K. K., Oza, A. M., Scott, C. L., Giordano, H., Sun, J., Konecny, G. E., Coleman, R. L., Tinker, A. V., O'Malley, D. M., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30559-9 · Cited by 1,196 · see citing works
Hamanishi, J., Mandai, M., Ikeda, T., Minami, M., Kawaguchi, A., Murayama, T., Kanai, M., Mori, Y., Matsumoto, S., Chikuma, S., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.62.3397 · Cited by 1,176 · see citing works
Gelmon, K. A., Tischkowitz, M. D., MacKay, H. J., Swenerton, K. D., Robidoux, A., Tonkin, K. S., Hirte, H. W., Huntsman, D. D., Clemons, M. J., Gilks, C. B., et al. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70214-5 · Cited by 1,117 · see citing works
Requirement of poly(ADP-ribose) polymerase in recovery from DNA damage in mice and in cells
Murcia, J. M., Niedergang, C., Trucco, C., Ricoul, M., Dutrillaux, B., Mark, M. P., Oliver, F. J., Masson, M., Dierich, A., LeMeur, M., et al. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.14.7303 · Cited by 1,058 · see citing works
Pennington, K. P., Walsh, T., Harrell, M. I., Lee, M. K., Pennil, C. C., Rendi, M. H., Thornton, A., Norquist, B. M., Casadei, S., Nord, A. S., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-2287 · Cited by 1,050 · see citing works
Rottenberg, S., Jaspers, J. E., Kersbergen, A. J., van der Burg, E., Nygren, A. O. H., Zander, S. A. L., Derksen, P. W. B., de Bruin, M., Zevenhoven, J., Lau, A., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0806092105 · Cited by 954 · see citing works
Homologous Recombination Deficiency: Exploiting the Fundamental Vulnerability of Ovarian Cancer
Konstantinopoulos, P. A., Ceccaldi, R., Shapiro, G. I., & D'Andrea, A. D. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0714 · Cited by 945 · see citing works
Mitotic homologous recombination maintains genomic stability and suppresses tumorigenesis
Moynahan, M. E., & Jasin, M. (2010) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2851 · Cited by 923 · see citing works
Poly(ADP-ribose) polymerase and the therapeutic effects of its inhibitors
Jagtap, P. G., & Szabó, C. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1718 · Cited by 896 · see citing works
Replication stress links structural and numerical cancer chromosomal instability
Burrell, R. A., McClelland, S. E., Endesfelder, D., Groth, P., Weller, M.-C., Shaikh, N., Domingo, E., Kanu, N., Dewhurst, S. M., Gronroos, E. C., et al. (2013) · Nature · doi:10.1038/nature11935 · Cited by 868 · see citing works
Ashworth, A. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.0812 · Cited by 857 · see citing works
Stereospecific PARP Trapping by BMN 673 and Comparison with Olaparib and Rucaparib
Murai, J., Huang, S.-Y. N., Renaud, A., Zhang, Y., Ji, J. J., Takeda, S., Morris, J., Teicher, B. A., Doroshow, J. H., & Pommier, Y. G. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-0803 · Cited by 760 · see citing works
Transcriptionally active chromatin recruits homologous recombination at DNA double-strand breaks
Aymard, F., Bugler, B., Schmidt, C. K., Guillou, E., Caron, P., Briois, S., Iacovoni, J. S., Daburon, V., Miller, K. M., Jackson, S. P., et al. (2014) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.2796 · Cited by 668 · see citing works
Friedman, L. S., Ostermeyer, E. A., Szabo, C. I., Dowd, P., Lynch, E. D., Rowell, S. E., & King, M. (1994) · Nature Genetics · doi:10.1038/ng1294-399 · Cited by 622 · see citing works
PARP is activated at stalled forks to mediate Mre11‐dependent replication restart and recombination
Bryant, H. E., Petermann, E., Schultz, N., Jemth, A., Loseva, O., Issaeva, N., Johansson, F., Fernandez, S., McGlynn, P., & Helleday, T. (2009) · The EMBO Journal · doi:10.1038/emboj.2009.206 · Cited by 593 · see citing works
Liu, J. F., Barry, W. T., Birrer, M. J., Lee, J.-M., Buckanovich, R. J., Fleming, G. F., Rimel, B. J., Buss, M. K., Nattam, S. R., Hurteau, J. A., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70391-2 · Cited by 583 · see citing works
Sandhu, S. K., Schelman, W. R., Wilding, G., Moreno, V., Baird, R. D., Miranda, S., Hylands, L., Riisnaes, R., Forster, M. D., Omlin, A. G., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70240-7 · Cited by 564 · see citing works
Oza, A. M., Cibula, D., Benzaquen, A. O., Poole, C. J., Mathijssen, R. H. J., Sonke, G. S., Colombo, N., Špaček, J., Vuylsteke, P., Hirte, H. W., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)71135-0 · Cited by 546 · see citing works
Patel, A. G., Sarkaria, J. N., & Kaufmann, S. H. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1013715108 · Cited by 543 · see citing works
Wagle, N., Berger, M. F., Davis, M. J., Blumenstiel, B. S., DeFelice, M. T., Pochanard, P., Ducar, M. D., Hummelen, P. V., MacConaill, L. E., Hahn, W. C., et al. (2011) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0184 · Cited by 526 · see citing works
Ledermann, J. A., Harter, P., Gourley, C., Friedlander, M. L., Vergote, I. B., Rustin, G. J. S., Scott, C. L., Meier, W., Shapira‐Frommer, R., Safra, T., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30376-x · Cited by 450 · see citing works
An update on PARP inhibitors—moving to the adjuvant setting
Sonnenblick, A., de Azambuja, E., Azim, H. A., & Piccart, M. J. (2014) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2014.163 · Cited by 374 · see citing works
Poly (ADP-Ribose) Polymerase Inhibitors: Recent Advances and Future Development
Scott, C. L., Swisher, E. M., & Kaufmann, S. H. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.58.8848 · Cited by 356 · see citing works
PARP Inhibitors for BRCA1/2 mutation-associated and BRCA-like malignancies
Lee, J.-M., Ledermann, J. A., & Kohn, E. C. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt384 · Cited by 352 · see citing works
Physiology and pathophysiology of poly(ADP‐ribosyl)ation *
Bürkle, A. (2001) · BioEssays · doi:10.1002/bies.1115 · Cited by 337 · see citing works
Treatment of recurrent ovarian cancer
Pignata, S., Cecere, S. C., du Bois, A., Harter, P., & Heitz, F. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx441 · Cited by 337 · see citing works
Watkins, J. A., Irshad, S., Grigoriadis, A., & Tutt, A. N. (2014) · Breast Cancer Research · doi:10.1186/bcr3670 · Cited by 327 · see citing works
Kummar, S., Kinders, R. J., Gutierrez, M. E., Rubinstein, L., Parchment, R. E., Phillips, L. R., Ji, J. J., Monks, A. P., Low, J. A., Chen, A. P., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.7681 · Cited by 327 · see citing works
PARP-3 and APLF Function Together to Accelerate Nonhomologous End-Joining
Rulten, S. L., Fisher, A. E. O., Robert, I., Zuma, M. C., Rouleau, M., Ju, L., Poirier, G. G., Reina‐San‐Martin, B., & Caldecott, K. W. (2011) · Molecular Cell · doi:10.1016/j.molcel.2010.12.006 · Cited by 326 · see citing works
Aghajanian, C. A., Goff, B. A., Nycum, L. R., Wang, Y. V., Husain, A., & Blank, S. V. (2015) · Gynecologic Oncology · doi:10.1016/j.ygyno.2015.08.004 · Cited by 321 · see citing works
Use of mutation profiles to refine the classification of endometrial carcinomas
McConechy, M. K., Ding, J., Cheang, M. C. U., Wiegand, K. C., Senz, J., Tone, A. A., Yang, W., Prentice, L., Tse, K., Zeng, T., et al. (2012) · The Journal of Pathology · doi:10.1002/path.4056 · Cited by 301 · see citing works
Functions of PARylation in DNA Damage Repair Pathways
Wei, H., & Yu, X. (2016) · Genomics Proteomics & Bioinformatics · doi:10.1016/j.gpb.2016.05.001 · Cited by 296 · see citing works
Domchek, S. M., Aghajanian, C. A., Shapira‐Frommer, R., Schmutzler, R. K., Audeh, M. W., Friedlander, M. L., Balmañà, J., Mitchell, G., Fried, G., Stemmer, S. M., et al. (2015) · Gynecologic Oncology · doi:10.1016/j.ygyno.2015.12.020 · Cited by 295 · see citing works
Genomic consequences of aberrant DNA repair mechanisms stratify ovarian cancer histotypes
Wang, Y. K., Bashashati, A., Anglesio, M. S., Cochrane, D. R., Grewal, D. S., Ha, G., McPherson, A., Horlings, H. M., Senz, J., Prentice, L., et al. (2017) · Nature Genetics · doi:10.1038/ng.3849 · Cited by 263 · see citing works
Coleman, R. L., Sill, M. W., Bell‐McGuinn, K. M., Aghajanian, C. A., Gray, H. J., Tewari, K. S., Rubin, S. C., Rutherford, T., Chan, J. K., Chen, A. P., et al. (2015) · Gynecologic Oncology · doi:10.1016/j.ygyno.2015.03.042 · Cited by 262 · see citing works
Unraveling the mechanism of BRCA2 in homologous recombination
Holloman, W. K. (2011) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.2096 · Cited by 220 · see citing works
Konecny, G. E., & Kristeleit, R. S. (2016) · British Journal of Cancer · doi:10.1038/bjc.2016.311 · Cited by 218 · see citing works
PARP inhibitors: Clinical utility and possibilities of overcoming resistance
Bitler, B. G., Watson, Z. L., Brubaker, L. W., & Behbakht, K. (2017) · Gynecologic Oncology · doi:10.1016/j.ygyno.2017.10.003 · Cited by 218 · see citing works
Colombo, N., Peiretti, M., Parma, G., Lapresa, M., Mancari, R., Carinelli, S. G., Sessa, C., & Castiglione, M. (2010) · Annals of Oncology · doi:10.1093/annonc/mdq244 · Cited by 185 · see citing works
Hu, Y., Petit, S. A., Ficarro, S. B., Toomire, K. J., Xie, A., Lim, E., Cao, S. A., Park, E., Eck, M. J., Scully, R., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0891 · Cited by 171 · see citing works
Kang, J., D’Andrea, A. D., & Kozono, D. (2012) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djs177 · Cited by 167 · see citing works
Drew, Y., Ledermann, J. A., Hall, G. D., Rea, D. W., Glasspool, R. M., Highley, M., Jayson, G. C., Sludden, J., Murray, J., Jamieson, D., et al. (2016) · British Journal of Cancer · doi:10.1038/bjc.2016.41 · Cited by 161 · see citing works
Matulonis, U. A., Penson, R. T., Domchek, S. M., Kaufman, B., Shapira‐Frommer, R., Audeh, M. W., Kaye, S. B., Molife, L. R., Gelmon, K. A., Robertson, J. D., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw133 · Cited by 159 · see citing works
Non-homologous end joining: Emerging themes and unanswered questions
Radhakrishnan, S. K., Jette, N., & Lees‐Miller, S. P. (2014) · DNA repair · doi:10.1016/j.dnarep.2014.01.009 · Cited by 131 · see citing works
Current status of poly(ADP-ribose) polymerase inhibitors and future directions
Ohmoto, A., & Yachida, S. (2017) · OncoTargets and Therapy · doi:10.2147/ott.s139336 · Cited by 130 · see citing works
PARP inhibitors in ovarian cancer
Ledermann, J. A. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw094 · Cited by 129 · see citing works
Mateo, J., Moreno, V., Gupta, A., Kaye, S. B., Dean, E. J., Middleton, M. R., Friedlander, M. L., Gourley, C., Plummer, R., Rustin, G. J. S., et al. (2016) · Targeted Oncology · doi:10.1007/s11523-016-0435-8 · Cited by 128 · see citing works
Cerrato, A., Morra, F., & Celetti, A. (2016) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-016-0456-2 · Cited by 127 · see citing works
Ma, Y., Lu, H., Schwarz, K., & Lieber, M. R. (2005) · Cell Cycle · doi:10.4161/cc.4.9.1977 · Cited by 112 · see citing works
Resistance to PARP-Inhibitors in Cancer Therapy
Montoni, A., Robu, M., Pouliot, É., & Shah, G. M. (2013) · Frontiers in Pharmacology · doi:10.3389/fphar.2013.00018 · Cited by 102 · see citing works
Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer
Mirza, M. R., Monk, B. J., Herrstedt, J., Oza, A. M., Mahner, S., Redondo, A., Fabbro, M., Ledermann, J. A., Lorusso, D., Vergote, I. B., et al. (2017) · Obstetrical & Gynecological Survey · doi:10.1097/ogx.0000000000000404 · Cited by 100 · see citing works
Strategies for Combining Immunotherapy with Radiation for Anticancer Therapy
Seyedin, S. N., Schoenhals, J. E., Lee, D. A., Cortez, M. A., Wang, X., Niknam, S., Tang, C. Z., Hong, D. S., Naing, A., Sharma, P., et al. (2015) · Immunotherapy · doi:10.2217/imt.15.65 · Cited by 92 · see citing works
Perspective on the Pipeline of Drugs Being Developed with Modulation of DNA Damage as a Target
Plummer, R. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-0984 · Cited by 90 · see citing works
Radiation Treatment in Women with Ovarian Cancer: Past, Present, and Future
Fields, E. C., McGuire, W. P., Lin, L. L., & Temkin, S. M. (2017) · Frontiers in Oncology · doi:10.3389/fonc.2017.00177 · Cited by 89 · see citing works
Poly(ADP-ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer
Tattersall, A., Ryan, N. A. J., Wiggans, A. J., Rogozińska, E., & Morrison, J. (2022) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007929.pub4 · Cited by 87 · see citing works
von Minckwitz, G., Müller, B. M., Loibl, S., Budczies, J., Hanusch, C. A., Darb‐Esfahani, S., Hilfrich, J., Weiss, E., Huober, J., Blohmer, J., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.31.9079 · Cited by 85 · see citing works
Base Excision Repair Defects Invoke Hypersensitivity to PARP Inhibition
Horton, J. K., Stefanick, D. F., Prasad, R., Gassman, N. R., Kedar, P. S., & Wilson, S. H. (2014) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-13-0502 · Cited by 82 · see citing works
Are Surveillance Procedures of Clinical Benefit for Patients Treated for Ovarian Cancer?
Gadducci, A., Fuso, L., Cosio, S., Landoni, F., Maggino, T., Perotto, S., Sartori, E., Testa, A. C., Galletto, L., & Zola, P. (2009) · International Journal of Gynecological Cancer · doi:10.1111/igc.0b013e3181a1cc02 · Cited by 78 · see citing works
Dhawan, M. S., Bartelink, I. H., Aggarwal, R. R., Leng, J. X., Zhang, J. Z., Pawłowska, N., Terranova-Barberio, M., Grabowsky, J. A., Gewitz, A. D., Chien, A. J., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-0703 · Cited by 78 · see citing works
First-in-human trial of novel oral PARP inhibitor BMN 673 in patients with solid tumors.
Bono, J. S. D., Mina, L. A., Gonzalez, M., Curtin, N. J., Wang, E., Henshaw, J. W., Chadha, M. K., Sachdev, J. C., Matei, D. E., Jameson, G., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.31.15_suppl.2580 · Cited by 76 · see citing works
Reiss, K. A., Herman, J. M., ZAHURAK, M. L., Brade, A. M., Dawson, L. A., Scardina, A., Joffe, C., Petito, E., Hacker‐Prietz, A., Kinders, R. J., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-1552 · Cited by 75 · see citing works
Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase
Bryant, H. E., Schultz, N., Thomas, H. D., Parker, K. M., Flower, D., Lopez, E., Kyle, S., Meuth, M., Curtin, N. J., & Helleday, T. (2007) · Nature · doi:10.1038/nature05789 · Cited by 70 · see citing works
Immune Checkpoint Inhibitors: A New Opportunity in the Treatment of Ovarian Cancer?
Mittica, G., Genta, S., Aglietta, M., & Valabrega, G. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17071169 · Cited by 65 · see citing works
Self-citationDevelopment of PARP inhibitors in oncology
Rodon, J. A., Iniesta, M. D., & Papadopoulos, K. P. (2008) · Expert Opinion on Investigational Drugs · doi:10.1517/13543780802525324 · Cited by 64 · see citing works
The Role of PARP Inhibitors in the Treatment of Gynecologic Malignancies
Reinbolt, R. E., & Hays, J. L. (2013) · Frontiers in Oncology · doi:10.3389/fonc.2013.00237 · Cited by 62 · see citing works
Puhalla, S., Beumer, J. H., Pahuja, S., Appleman, L. J., Tawbi, H. A.-H., Stoller, R. G., Lee, J. J., Lin, Y., Kiesel, B. F., Yu, J., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.32.15_suppl.2570 · Cited by 62 · see citing works
The role of tandem duplicator phenotype in tumour evolution in high‐grade serous ovarian cancer
Ng, C. K. Y., Cooke, S. L., Howe, K., Newman, S., Xian, J., Temple, J., Batty, E. M., Pole, J. C. M., Langdon, S. P., Edwards, P. A., et al. (2011) · The Journal of Pathology · doi:10.1002/path.3980 · Cited by 61 · see citing works
Genomic signatures as predictive biomarkers of homologous recombination deficiency in ovarian cancer
Vanderstichele, A., Busschaert, P., Olbrecht, S., Lambrechts, D., & Vergote, I. B. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2017.08.029 · Cited by 61 · see citing works
Thigpen, J. T. (2012) · Yearbook of Oncology · doi:10.1016/j.yonc.2012.08.001 · Cited by 50 · see citing works
Dungan, J. S. (2012) · Yearbook of Obstetrics Gynecology and Women s Health · doi:10.1016/j.yobg.2012.06.161 · Cited by 48 · see citing works
Murata, S., Zhang, C., Finch, N., Zhang, K., Campo, L., & Breuer, E.-K. Y. (2016) · BioMed Research International · doi:10.1155/2016/2346585 · Cited by 47 · see citing works
Landrum, L. M., Brady, W. E., Armstrong, D. K., Moore, K. N., DiSilvestro, P., O’Malley, D. M., Tenney, M. E., Rose, P. G., & Fracasso, P. M. (2015) · Gynecologic Oncology · doi:10.1016/j.ygyno.2015.11.024 · Cited by 42 · see citing works
Lynch, H. T., Conway, T., & Lynch, J. (1991) · Cancer Genetics and Cytogenetics · doi:10.1016/0165-4608(91)90094-b · Cited by 41 · see citing works
Boehler, C., & Dantzer, F. (2011) · Cell Cycle · doi:10.4161/cc.10.7.15169 · Cited by 36 · see citing works
Phase 1/2 study of oral rucaparib: Final phase 1 results.
Kristeleit, R. S., Burris, H. A., LoRusso, P. M., Patel, M. R., Asghar, U. S., El-Khouly, F., Calvert, H., Infante, J. R., Hilton, J. F., Tolaney, S. M., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.32.15_suppl.2573 · Cited by 27 · see citing works
Nishio, S., Takekuma, M., Takeuchi, S., Kawano, K., Tsuda, N., Tasaki, K., Takahashi, N., Abé, M., Tanaka, A., Nagasawa, T., et al. (2017) · Cancer Science · doi:10.1111/cas.13381 · Cited by 23 · see citing works
Friedlander, M. L., Gebski, V., Gibbs, E., Bloomfield, R., Hilpert, F., Wenzel, L. B., Joly, F., Eek, D., Rodrigues, M. J., Clamp, A. R., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.35.15_suppl.5507 · Cited by 18 · see citing works
Lin, K., Sun, J. X., Maloney, L., Goble, S. M., Oza, A. M., Coleman, R., Scott, C. L., Robillard, L., Mann, E., Isaacson, J., et al. (2015) · European Journal of Cancer · doi:10.1016/s0959-8049(16)31469-1 · Cited by 15 · see citing works
Long-term benefit of niraparib treatment of recurrent ovarian cancer (OC).
Matulonis, U. A., Herrstedt, J., Tinker, A. V., Marmé, F., Redondo, A., Kalbacher, E., Ledermann, J. A., Pikiel, J., Christensen, R. D., Berek, J. S., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.35.15_suppl.5534 · Cited by 14 · see citing works
Mirza, M. R., Monk, B. J., Gil-Martín, M., Gilbert, L., Canzler, U., Follana, P., Waters, J. S., Kridelka, F., Levy, T., Benigno, B. B., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.35.15_suppl.5517 · Cited by 10 · see citing works
Campo, J. M. D., Mirza, M. R., Berek, J. S., Provencher, D. M., Emons, G., Fabbro, M., Lord, R., Colombo, N., Petru, E., Wenham, R. M., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.35.15_suppl.5560 · Cited by 8 · see citing works
Flagged first, then by citations
1 of the 100 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Discovering Anti-Cancer Drugs via Computational Methods
Cui, W., Aouidate, A., Wang, S., Yu, Q., Li, Y.-H., & Yuan, S. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.00733 · Cited by 310 · see citing works
Zhao, Y., Cao, J., Melamed, A., Worley, M. J., Gockley, A. A., Jones, D., Nia, H. T., Zhang, Y., Stylianopoulos, T., Kumar, A. S., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1818357116 · Cited by 262 · see citing works
Exploiting DNA repair defects in colorectal cancer
Reilly, N. M., Novara, L., Nicolantonio, F. D., & Bardelli, A. (2019) · Molecular Oncology · doi:10.1002/1878-0261.12467 · Cited by 129 · see citing works
Cecere, S. C., Giannone, G., Salutari, V., Arenare, L., Lorusso, D., Ronzino, G., Lauria, R., Cormio, G., Carella, C., Scollo, P., et al. (2019) · Gynecologic Oncology · doi:10.1016/j.ygyno.2019.10.023 · Cited by 106 · see citing works
Self-citationBorella, F., Ghisoni, E., Giannone, G., Cosma, S. D., Benedetto, C., Valabrega, G., & Katsaros, D. (2020) · Diagnostics · doi:10.3390/diagnostics10030146 · Cited by 94 · see citing works
Self-citationValabrega, G., Scotto, G., Tuninetti, V., Pani, A., & Scaglione, F. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22084203 · Cited by 93 · see citing works
Self-citationCésaire, M., Thariat, J., Candéias, S. M., Stefan, D., Saintigny, Y., & Chevalier, F. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19123793 · Cited by 84 · see citing works
The Role of ARID1A in Tumors: Tumor Initiation or Tumor Suppression?
Xu, S., & Tang, C. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.745187 · Cited by 80 · see citing works
Nanoparticles in precision medicine for ovarian cancer: From chemotherapy to immunotherapy
Li, Y., Gao, Y., Zhang, X., Guo, H., & Gao, H. (2020) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2020.119986 · Cited by 68 · see citing works
Recent advancements of antiangiogenic combination therapies in ovarian cancer
An, D., Banerjee, S. N., & Lee, J. (2021) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2021.102224 · Cited by 66 · see citing works
Brain Metastases from Ovarian Cancer: Current Evidence in Diagnosis, Treatment, and Prognosis
Borella, F., Bertero, L., Morrone, A., Gambella, A., Bovetti, M., Cosma, S. D., Carosso, A. R., Katsaros, D., Gemmiti, S., Preti, M., et al. (2020) · Cancers · doi:10.3390/cancers12082156 · Cited by 55 · see citing works
Self-citationIGF2BP1 is a targetable SRC/MAPK-dependent driver of invasive growth in ovarian cancer
Bley, N., Schott, A., Müller, S., Misiak, D., Lederer, M., Fuchs, T., Aßmann, C., Glaß, M., Ihling, C. H., Sinz, A., et al. (2020) · RNA Biology · doi:10.1080/15476286.2020.1812894 · Cited by 51 · see citing works
Li, Y., Wang, Y., Zhang, W., Wang, X., Chen, L., & Wang, S. (2021) · Scientific Reports · doi:10.1038/s41598-021-82990-y · Cited by 46 · see citing works
Ofori, S., & Awuah, S. G. (2019) · ACS Omega · doi:10.1021/acsomega.9b01106 · Cited by 41 · see citing works
Molecular Mechanisms of PARP-1 Inhibitor 7-Methylguanine
Nilov, D. K., Maluchenko, N. V., Kurgina, T. A., Pushkarev, S. V., Lys, A., Kutuzov, M. M., Gerasimova, N. S., Feofanov, A. V., Švedas, V. K., Lavrik, O. I., et al. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21062159 · Cited by 36 · see citing works
Tao, M., & Wu, X. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-021-02139-7 · Cited by 35 · see citing works
Young, R. J., França, P. D. D. S., Pirovano, G., Piotrowski, A. F., Nicklin, P. J., Riedl, C. C., Schwartz, J., Bale, T., Donabedian, P. L., Kossatz, S., et al. (2020) · Neuro-Oncology Advances · doi:10.1093/noajnl/vdaa119 · Cited by 35 · see citing works
DNA N6-Methyladenine (6mA) Modification Regulates Drug Resistance in Triple Negative Breast Cancer
Sheng, X., Wang, J., Guo, Y. F., Zhang, J., & Luo, J. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2020.616098 · Cited by 34 · see citing works
Han, Y., Chen, M., Wang, H.-L., Hsu, J. L., Li, C.-W., Chu, Y., Liu, C., Nie, L., Chan, L.-C., Yam, C., et al. (2019) · Europe PMC (PubMed Central) · Cited by 33 · see citing works
Putri, J. F., Bhargava, P., Dhanjal, J. K., Yaguchi, T., Sundar, D., Kaul, S. C., & Wadhwa, R. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-019-1500-9 · Cited by 33 · see citing works
Comprehensive analysis of prognostic gene signatures based on immune infiltration of ovarian cancer
Yan, S.-B., Fang, J., Chen, Y., Xie, Y., Zhang, S., Zhu, X., & Fang, F. (2020) · BMC Cancer · doi:10.1186/s12885-020-07695-3 · Cited by 31 · see citing works
Molecular mechanisms of cisplatin resistance in ovarian cancer
Jiang, C., Shen, C., Ni, M., Huang, L., Hu, H., Dai, Q. Y., Zhao, H., & Zhu, Z. (2023) · Genes & Diseases · doi:10.1016/j.gendis.2023.06.032 · Cited by 27 · see citing works
Clinical Implications of DNA Repair Defects in High-Grade Serous Ovarian Carcinomas
Milanesio, M. C., Giordano, S., & Valabrega, G. (2020) · Cancers · doi:10.3390/cancers12051315 · Cited by 26 · see citing works
Self-citationManasaryan, G., Suplatov, D. A., Pushkarev, S. V., Drobot, V., Kuimov, A. N., Švedas, V. K., & Nilov, D. K. (2021) · Cancers · doi:10.3390/cancers13061201 · Cited by 27 · see citing works
Pagkali, A., Mamais, I., Michalinos, A., & Agouridis, A. P. (2022) · Current Oncology · doi:10.3390/curroncol29010029 · Cited by 26 · see citing works
Xue, Y., Yin, T., Yuan, S., Wang, L., Lin, H., Jin, T., Xu, R., Gu, J., Shen, S., Chen, X., et al. (2024) · Drug Resistance Updates · doi:10.1016/j.drup.2024.101151 · Cited by 25 · see citing works
PRMT1 Confers Resistance to Olaparib via Modulating MYC Signaling in Triple-Negative Breast Cancer
Hsu, W.-J., Chen, C., Chang, Y., Cheng, C., Tsai, Y.-H., & Lin, C. (2021) · Journal of Personalized Medicine · doi:10.3390/jpm11101009 · Cited by 25 · see citing works
Therapeutic Strategies and Biomarkers to Modulate PARP Activity for Targeted Cancer Therapy
Singh, N., Pay, S. L., Bhandare, S. B., Arimpur, U., & Motea, E. A. (2020) · Cancers · doi:10.3390/cancers12040972 · Cited by 24 · see citing works
Sauriol, S. A., Carmona, E., Udaskin, M. L., Radulovich, N., Leclerc-Desaulniers, K., Rottapel, R. K., Oza, A. M., Lheureux, S., Provencher, D. M., & Mes‐Masson, A. (2023) · Scientific Reports · doi:10.1038/s41598-023-30081-5 · Cited by 24 · see citing works
Labrie, M., Kim, T., Ju, Z., Lee, S., Zhao, W., Fang, Y., Lu, Y., Chen, K., Ramirez, P. T., Frumovitz, M., et al. (2019) · Oncotarget · doi:10.18632/oncotarget.26947 · Cited by 24 · see citing works
Huang, X., Li, X., Shan, W., Chen, Y., Zhu, Q., & Xia, B.-R. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1131342 · Cited by 23 · see citing works
Umar, H., Wahab, H. A., Attiq, A., Amjad, M. W., Bukhari, S. N. A., & Ahmad, W. (2024) · Mutation research. Fundamental and molecular mechanisms of mutagenesis · doi:10.1016/j.mrfmmm.2024.111856 · Cited by 20 · see citing works
High Expression of MYL9 Indicates Poor Clinical Prognosis of Epithelial Ovarian Cancer
Deng, Y., Liu, L., Feng, W., Lin, Z., Ning, Y., & Luo, X. (2021) · Recent Patents on Anti-Cancer Drug Discovery · doi:10.2174/1574891x16666210706153740 · Cited by 21 · see citing works
Clinical Pharmacokinetics and Pharmacodynamics of Rucaparib
Liao, M., Beltman, J., Giordano, H., Harding, T. C., Maloney, L., Simmons, A. D., & Xiao, J. J. (2022) · Clinical Pharmacokinetics · doi:10.1007/s40262-022-01157-8 · Cited by 20 · see citing works
Feng, Z., Yang, X.-B., Tian, M., Zeng, N., Bai, Z., Deng, W., Zhao, Y., Guo, J.-H., Yang, Y.-C., Zhang, Z.-T., et al. (2023) · BMC Cancer · doi:10.1186/s12885-023-11328-w · Cited by 18 · see citing works
Alemzadeh, E., Allahqoli, L., Mazidimoradi, A., Alemzadeh, E., Ghasemi, F., Salehiniya, H., & Alkatout, İ. (2024) · Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics · doi:10.32604/or.2024.031006 · Cited by 19 · see citing works
Pyrrolo[2,1-f][1,2,4]triazine: a promising fused heterocycle to target kinases in cancer therapy
Singh, S., Utreja, D., & Kumar, V. (2021) · Medicinal Chemistry Research · doi:10.1007/s00044-021-02819-1 · Cited by 17 · see citing works
Mainstreaming genetic counseling for BRCA testing into oncology clinics – Indian perspective
Verma, A. K., Nag, S. M., Hasan, Q. A., & Selvakumar, V. P. P. (2019) · Indian Journal of Cancer · doi:10.4103/ijc.ijc_458_19 · Cited by 17 · see citing works
Choi, P. J., Cooper, E. A., Schweder, P. M., Mee, E. T., Turner, C. P., Faull, R. L. M., Denny, W. A., Dragunow, M., Park, T., & Jose, J. (2020) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2020.127252 · Cited by 17 · see citing works
Sun, G., Miao, G., Li, Z., Zheng, W., Zhou, C., Sun, G., Cao, H., Li, Z., & Tang, W. (2022) · Journal of Oncology · doi:10.1155/2022/6988923 · Cited by 17 · see citing works
Modeling of the Enzyme—Substrate Complexes of Human Poly(ADP-Ribose) Polymerase 1
Nilov, D. K., Pushkarev, S. V., Gushchina, I. V., Manasaryan, G., Игоревич, К. К., & Švedas, V. K. (2020) · Biochemistry (Moscow) · doi:10.1134/s0006297920010095 · Cited by 17 · see citing works
ATR Inhibitors in Platinum-Resistant Ovarian Cancer
Li, S., Wang, T., Fei, X., & Zhang, M. (2022) · Cancers · doi:10.3390/cancers14235902 · Cited by 16 · see citing works
Toxicological Properties of 7-Methylguanine, and Preliminary Data on its Anticancer Activity
Игоревич, К. К., Fetisov, T. I., Antoshina, E. E., Trukhanova, L. S., Gorkova, T. G., Vlasova, O. A., Александровна, Х. И., Lesovaya, E. A., Kulbachevskaya, N. Y., Shcherbakova, T. A., et al. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.842316 · Cited by 15 · see citing works
The power and the promise of synthetic lethality for clinical application in cancer treatment
Liu, Q., Yang, Z., Tang, Q.-H., Wang, W.-E., Chu, D.-S., Ji, J.-F., Fan, Q.-Y., Jiang, H., Yang, Q.-X., Zhang, H., et al. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.116288 · Cited by 16 · see citing works
GNAi2/gip2-Regulated Transcriptome and Its Therapeutic Significance in Ovarian Cancer
Ha, J. H., Jayaraman, M., Yan, M., Dhanasekaran, P., Isidoro, C., Song, Y. S., & Dhanasekaran, D. N. (2021) · Biomolecules · doi:10.3390/biom11081211 · Cited by 15 · see citing works
Veliparib: A New Therapeutic Option In Ovarian Cancer?
Ghisoni, E., Giannone, G., Tuninetti, V., Genta, S., Scotto, G., Aglietta, M., Sangiolo, D., Mittica, G., & Valabrega, G. (2019) · Future Oncology · doi:10.2217/fon-2018-0883 · Cited by 15 · see citing works
Self-citationStubbs, F. E., Flynn, B. P., Rivers, C. A., Birnie, M. T., Herman, A., Swinstead, E. E., Baek, S., Fang, H., Temple, J., Carroll, J. S., et al. (2022) · Oncogene · doi:10.1038/s41388-022-02516-2 · Cited by 15 · see citing works
Zhou, X., Zhang, H., Duan, Y., Zhu, J., & Dai, H. (2022) · Journal of Clinical Laboratory Analysis · doi:10.1002/jcla.24813 · Cited by 14 · see citing works
The Role of NAD+, SIRTs Interactions in Stimulating and Counteracting Carcinogenesis
Podyacheva, E., & Toropova, Y. G. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24097925 · Cited by 14 · see citing works
The Next Frontier in Pancreatic Cancer: Targeting the Tumor Immune Milieu and Molecular Pathways
Yin, C., Alqahtani, A. J., & Noel, M. S. (2022) · Cancers · doi:10.3390/cancers14112619 · Cited by 14 · see citing works
Zhao, D., Long, X., & Wang, J. (2022) · Drug Design Development and Therapy · doi:10.2147/dddt.s387920 · Cited by 14 · see citing works
Cao, Q., Li, L., Zhao, Y., Wang, C., Shi, Y., Tao, X., Cai, C., & Han, X. (2023) · Cell Transplantation · doi:10.1177/09636897231187996 · Cited by 13 · see citing works
Wang, L., Wang, Q., Xu, Y., Cui, M., & Han, L. (2019) · Current Drug Targets · doi:10.2174/1389450120666190925123507 · Cited by 13 · see citing works
Cheng, H., Yang, J., Liu, H., & Xiang, Y. (2021) · Archives of Gynecology and Obstetrics · doi:10.1007/s00404-021-06070-2 · Cited by 13 · see citing works
CRISPR screens guide the way for PARP and ATR inhibitor biomarker discovery
Schleicher, E. M., & Moldovan, G. (2021) · FEBS Journal · doi:10.1111/febs.16217 · Cited by 13 · see citing works
Effective natural inhibitors targeting poly ADP-ribose polymerase by computational study
Zhong, S., Wu, B., Yang, W., Ge, J., Zhang, X., Chen, Z., Duan, H., He, Z., Liu, Y., Wang, H., et al. (2021) · Aging · doi:10.18632/aging.103986 · Cited by 13 · see citing works
ETS transcription factor ELK3 in human cancers: An emerging therapeutic target
Al-Hawary, S. I. S., Pallathadka, H., Hjazi, A. M., Zhumanov, Z. E., Alazbjee, A. A. A., Imad, S., Alsalamy, A., Hussien, B. M., Jafer, N. S., & Mahmoudi, R. (2023) · Pathology - Research and Practice · doi:10.1016/j.prp.2023.154728 · Cited by 12 · see citing works
Kelly, T. E., Spillane, C. D., Ward, M. P., Hokamp, K., Huang, Y., Tewari, P., Martin, C. M., Norris, L., Mohamed, B. M., Bates, M., et al. (2023) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2023.1150991 · Cited by 12 · see citing works
Phase I Pharmacokinetic Study of Niraparib in Chinese Patients with Epithelial Ovarian Cancer
Zhang, J., Zheng, H., Gao, Y., Lou, G., Yin, R., Ji, D., Li, W., Wang, W., Xia, B., Wang, D., et al. (2019) · The Oncologist · doi:10.1634/theoncologist.2019-0565 · Cited by 12 · see citing works
Preclinical immunotherapy with Cytokine-Induced Killer lymphocytes against epithelial ovarian cancer
Capellero, S., Erriquez, J., Melano, C., Mesiano, G., Genta, S., Pisacane, A. M., Mittica, G., Ghisoni, E., Olivero, M., Renzo, M. F. D., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-63634-z · Cited by 13 · see citing works
Self-citationPlasma Protein Biomarkers Associated with Higher Ovarian Cancer Risk in BRCA1/2 Carriers
Ahn, H., Yoon, S. M., Yu, J., Yeom, J., Lee, S., Hur, S. Y., Jung, Y., Kim, K., & Choi, Y. J. (2021) · Cancers · doi:10.3390/cancers13102300 · Cited by 12 · see citing works
Zhao, D., Long, X., & Wang, J. (2023) · Oncology Letters · doi:10.3892/ol.2023.13747 · Cited by 12 · see citing works
Peng, X., Li, Y., Qu, J., Jiang, L., Wu, K., Liu, D., Chen, Y., Peng, J., Guo, Y., & Cao, X. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.116405 · Cited by 11 · see citing works
Huang, J., Li, L., Tan, X., Wu, Z., Chen, D.-W., & Luo, X. (2022) · Current Pharmaceutical Design · doi:10.2174/1381612828666220610164100 · Cited by 11 · see citing works
Combined treatment of disulfiram with PARP inhibitors suppresses ovarian cancer
Tang, B., Wu, M. Y., Zhang, L., Jian, S., Lv, S., Lin, T., Zhu, S., Liu, L., Wang, Y., Yi, Z., et al. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1154073 · Cited by 11 · see citing works
Zhao, D., Long, X., & Wang, J. (2021) · Oncology Reports · doi:10.3892/or.2021.8231 · Cited by 12 · see citing works
Liu, X.-M., Zhu, Z., Li, Q., Li, Z., Rong, R., Xie, C., Qiao, X., Feng, Y., & Xu, J. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c01170 · Cited by 10 · see citing works
PARP inhibitors and breast cancer: from therapeutic breakthrough to resistance challenge
Wang, W., Cai, C., Qin, S., He, L., Liang, Q., Siyao, T., Xie, J., Long, T., Hou, J., Kim, W., et al. (2026) · Experimental & Molecular Medicine · doi:10.1038/s12276-026-01673-8 · Cited by 10 · see citing works
Kausar, M. A., Alshammari, K. F., Alenazi, F., Anwar, S., Khalifa, A. M., Ginawi, T., Asiri, A., Najm, M. Z., Rabbani, S. A., El‐Tanani, M., et al. (2025) · International Journal of Oncology · doi:10.3892/ijo.2025.5771 · Cited by 11 · see citing works
Dose-dense chemotherapy with weekly paclitaxel and 3-weekly carboplatin for recurrent ovarian cancer
Chen, W., Huang, H., Chang, T., & Chou, H. (2020) · Taiwanese Journal of Obstetrics and Gynecology · doi:10.1016/j.tjog.2019.10.003 · Cited by 10 · see citing works
Pre-Existing and Acquired Resistance to PARP Inhibitor-Induced Synthetic Lethality
Le, B. V., Podszywalow‐Bartnicka, P., Piwocka, K., & Skórski, T. (2022) · Cancers · doi:10.3390/cancers14235795 · Cited by 9 · see citing works
Malignancy in Abdominal Wall Endometriosis: Is There a Way to Avoid It? A Systematic Review
Alaert, J., Lancelle, M., Timmermans, M., Tanos, P., Nisolle, M., & Karampelas, S. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13082282 · Cited by 9 · see citing works
“Resistance to platinum-based chemotherapy may explain the dark outcomes in malignant AWE, but it remains to be determined whether PARPis have a therapeutic place in recurrent malignant AWE [60].”
BackgroundTargeting TRIP13 for overcoming anticancer drug resistance (Review)
Zhao, L., Ye, S., Jing, S., Gao, Y., & He, T. (2023) · Oncology Reports · doi:10.3892/or.2023.8639 · Cited by 9 · see citing works
Hydrophobic tagging: A promising paradigm for targeted protein degradation
Xin, L.-L., Wang, H., Yang, M., Guo, Z., Zhu, M., Moore, T. W., Dong, C.-N., & Zhou, H.-B. (2025) · Cell Insight · doi:10.1016/j.cellin.2025.100295 · Cited by 7 · see citing works
van den Pol, A. N., Zhang, X., Lima, E., Pitruzzello, M. C., Albayrak, N., Alvero, A. B., Davis, J. N., & Mor, G. (2020) · Virology · doi:10.1016/j.virol.2020.10.009 · Cited by 9 · see citing works
Zannini, G., Facchini, G., SIO, M. D., Vita, F. D., Ronchi, A., Orditura, M., Vietri, M. T., Ciardiello, F., Franco, R., Accardo, M., et al. (2023) · Pathology - Research and Practice · doi:10.1016/j.prp.2023.154336 · Cited by 9 · see citing works
VPS33B interacts with NESG1 to suppress cell growth and cisplatin chemoresistance in ovarian cancer
Ning, Y., Zeng, Z., Deng, Y., Feng, W., Huang, L., Liu, H., Lin, J., Zhang, C., Fan, Y., & Liu, L. (2021) · Cancer Science · doi:10.1111/cas.14864 · Cited by 9 · see citing works
Recent Progress in the Research on Benzimidazole PARP-1 Inhibitors
Cao, X., Wu, K., Chen, M., Peng, X., Li, Y., Tang, G., & Peng, J. (2022) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/1389557522666220321150700 · Cited by 8 · see citing works
McMahon, J. T., Faraj, R. R., & Adamson, D. C. (2020) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2020.1836154 · Cited by 8 · see citing works
Molecular Methods for Increasing the Effectiveness of Ovarian Cancer Treatment: A Systematic Review
Chilimoniuk, Z., Rocka, A. A., Stefaniak, M., Tomczyk, Z., Jasielska, F., Madras, D. K., & Filip, A. A. (2022) · Future Oncology · doi:10.2217/fon-2021-0565 · Cited by 8 · see citing works
Zitzmann-Kolbe, S., Kristian, A., Zopf, D., Kamfenkel, C., Politz, O., Ellingsen, C., Hilbig, J., Juul, M. U., Fonslet, J., Nielsen, C. H., et al. (2023) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-22-0808 · Cited by 7 · see citing works
Biomarkers of Central Nervous System Involvement from Epithelial Ovarian Cancer
Scotto, G., Borella, F., Turinetto, M., Tuninetti, V., Valsecchi, A. A., Giannone, G., Cosma, S. D., Benedetto, C., & Valabrega, G. (2021) · Cells · doi:10.3390/cells10123408 · Cited by 8 · see citing works
Self-citationLi, Z., Li, N., Noah, M. L. N., Shao, Q., & Zhan, X. (2024) · The EPMA Journal · doi:10.1007/s13167-024-00385-1 · Cited by 6 · see citing works
Li, H., Wu, H., Li, S., Wang, Q., Li, G., Ma, X., Gong, Y., Chu, Y., Jin, S., Chen, X., et al. (2025) · iScience · doi:10.1016/j.isci.2025.112860 · Cited by 6 · see citing works
Olaparib attenuates sepsis-induced acute multiple organ injury via ERK-mediated CD14 expression
Chen, Z., Chen, Y., Jin, X., Liu, Y., Shao, Z., & Li, Q. (2021) · Experimental Biology and Medicine · doi:10.1177/15353702211015620 · Cited by 6 · see citing works
Genomic instability in ovarian cancer: Through the lens of single nucleotide polymorphisms
Sistla, H. C., Talluri, S., Rajagopal, T., Venkatabalasubramanian, S., & Dunna, N. R. (2024) · Clinica Chimica Acta · doi:10.1016/j.cca.2024.119992 · Cited by 7 · see citing works
Kurgina, T. A., Shram, S. I., Kutuzov, M. M., Abramova, T. V., Shcherbakova, T. A., Maltseva, E. A., Poroikov, V., Lavrik, O. I., Švedas, V. K., & Nilov, D. K. (2022) · Biochemistry (Moscow) · doi:10.1134/s0006297922080132 · Cited by 6 · see citing works
Wu, D., Liu, J., Yu, L., Wu, S., & Qiu, X. (2022) · Journal of Ovarian Research · doi:10.1186/s13048-022-01048-3 · Cited by 6 · see citing works
PARP inhibitor-related haemorrhages: What does the real-world study say?
Wang, S., Guo, M., Zhang, X., Fan, P., & Jin, Z. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1070343 · Cited by 6 · see citing works
The Utility of NGS Analysis in Homologous Recombination Deficiency Tracking
Tsantikidi, A., Papadopoulou, E., Metaxa-Mariatou, V., Metaxa-Mariatou, V., Kapetsis, G., Florou-Chatzigiannidou, C., Meintani, A., Gazouli, M., PAPADIMITRIOU, C. A., Timotheadou, E. T., et al. (2023) · Diagnostics · doi:10.3390/diagnostics13182962 · Cited by 8 · see citing works
Schossig, P., Coskun, E., Arsenić, R., Horst, D. A., Sehouli, J., Bergmann, E. C., Andresen, N., Sigler, C., Busse, A., Keller, U. B., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24032292 · Cited by 5 · see citing works
Andersen, L. V. B., Larsen, M. J., Davies, H. R., Degasperi, A., Nielsen, H. R., Jensen, L. A., Kroeldrup, L., Gerdes, A., Lænkholm, A., Kruse, T. A., et al. (2023) · Breast Cancer Research · doi:10.1186/s13058-023-01655-y · Cited by 5 · see citing works
Priya, M. G. R., Manisha, J., Lazar, L. P. M., Rathore, S. S. S., & Solomon, V. R. (2024) · Current Computer - Aided Drug Design · doi:10.2174/0115734099283410240406064042 · Cited by 4 · see citing works
Probing the Cytotoxic Signaling Induced by Eupenifeldin in Ovarian Cancer Models
Maldonado, A. C., Haughan, M. A., Khin, M., Ekiert, J., Zhang, Z., Lantvit, D. D., Subeh, Z. Y. A., Pierre, H. C., Salkovski, M., Hirschhorn, T., et al. (2023) · Journal of Natural Products · doi:10.1021/acs.jnatprod.3c00186 · Cited by 4 · see citing works
Cheng, J., Sun, Y., Zhao, H., Ren, W., Gao, D., Wang, Z., Lv, W., & Dong, Q. (2023) · PeerJ · doi:10.7717/peerj.16314 · Cited by 4 · see citing works
Lung Cancer Clinical Trials in Latin America in the Era of Cooperative Groups: A 20-Year Analysis
Knapp, T. M., Nygaard, J., Cassinat, J. J., Galvez, F., & Gopalan, P. K. (2024) · JCO Global Oncology · doi:10.1200/go.23.00379 · Cited by 4 · see citing works
Li, J., Yang, J., & Wang, Y. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1542646 · Cited by 4 · see citing works
Shram, S. I., Shcherbakova, T. A., Abramova, T. V., Baradieva, E. C., Efremova, A. S., Smirnovskaya, M. S., Silnikov, V. N., Švedas, V. K., & Nilov, D. K. (2023) · Biochemistry (Moscow) · doi:10.1134/s0006297923060068 · Cited by 4 · see citing works
Mustafa, M. T., Abushanab, A. K., Mousa, M. T., Qawaqzeh, R. A., Alakhras, H. M., Othman, A. S., & Saed, A. (2024) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2024.2309177 · Cited by 4 · see citing works
The Utility of Comprehensive NGS Analysis in Homologous Recombination Deficiency TrackingPreprint
Tsantikidi, A., Papadopoulou, E., Tsaousis, G., Metaxa-Mariatou, V., Kapetsis, G., Florou-Chatzigiannidou, C., Meintani, A., Gazouli, M., PAPADIMITRIOU, C. A., Timotheadou, E. T., et al. (2023) · Preprints.org · doi:10.20944/preprints202307.0781.v1 · Cited by 4 · see citing works
- Authors
- Mittica, G., Ghisoni, E., Giannone, G., Genta, S., Aglietta, M., Sapino, A., & Valabrega, G.
- Affiliations
- Candiolo Cancer Institute (IT)
- Corresponding author
- Valabrega, Giorgio
- Venue
- Recent Patents on Anti-Cancer Drug Discovery
- Publisher
- Bentham Science Publishers Ltd.
- Published
- 2018-10-03
- Volume
- 13
- Issue
- 4
- Pages
- 392-410
- ISSN
- 1574-8928 (ISSN-L)
- OpenAlex
- W2794128499
- Cited by
- 158
- References
- 100
- Citations by year
- 2026: 5 · 2025: 16 · 2024: 21 · 2023: 29 · 2022: 20 · 2021: 27 · 2020: 28 · 2019: 11 · 2018: 1
- FWCI
- 6.28
- Type
- journal article
- Language
- en
- Open access
- green
- hdl.handle.net
- Licence
- other-oa
- Locations
- Recent Patents on Anti-Cancer Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- Institutional Research Information System University of Turin (University of Turin) (submittedVersion, other-oa)
- Topics
- Health Sciences › Medicine › Oncology › PARP inhibition in cancer therapy
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › BRCA gene mutations in cancer
- Health Sciences › Medicine › Reproductive Medicine › Ovarian cancer diagnosis and treatment
- Keywords
- PARP inhibitors, epithelial ovarian cancer, recurrent ovarian cancer, olaparib, niraparib, rucaparib, talazoparib, veliparib, BRCA mutations, platinum resistance, secondary resistance, mechanism of action, pharmacokinetics, neoadjuvant therapy, first-line therapy, combination therapy
- MeSH terms
- Poly(ADP-ribose) Polymerase Inhibitors, Animals, Antineoplastic Agents, Female, Humans, Ovarian Neoplasms, Phthalazines, Piperazines, Drug Resistance, Neoplasm
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
